Moore E, Bergamo R, Casella R
AstraZeneca, a Business Unit of Zeneca, Incorporated, 1800 Concord Pike, Wilmington, DE 19850-5437.
Drug Dev Ind Pharm. 2000 Dec;26(12):1259-70. doi: 10.1081/ddc-100102307.
A series of four beta-cyclodextrin complexes (called products) was formed by neutralizing an acidic drug to study the effect of drug solubility on complex formation and the dissolution performance from direct compression tablets. Four solid products were prepared by neutralizing the drug in 0.05, 0.10, 0.20, and 0.30 M tromethamine solutions with a constant 0.09 M beta-cyclodextrin concentration, filtering the solutions, and removing the water through evaporation with heat and vacuum. The four products contained drug and water in a distinct relationship, thus suggesting a complex formation that was dependent on the tromethamine concentration. Infrared, powder X-ray diffraction, differential scanning calorimetry (DSC), phase solubility, and scanning electron microscopy (SEM) techniques revealed distinct differences among the four products, suggesting three of the four products were complexes, and one product was either a weak complex or a physical mixture. Ultraviolet (UV) analysis showed no evidence of complex formation. Phase solubility results showed one product had a slight increase in drug solubility, and three products had no increase in drug solubility with increasing beta-cyclodextrin concentration. The lack of a solubility increase suggests insoluble complex formation. Drug dissolution in water was improved significantly in all tablets containing either a product or a physical mixture when compared to the pure drug. The products prepared with the two highest concentrations of tromethamine showed a dissolution performance that was superior to all other formulations. Enthalpy measurements by DSC were a good indicator of dissolution performance for tablets containing the four products. Drug dissolution through salt formation in the absence of beta-cyclodextrin showed the drug-salt dissolution varied from better to worse when compared to the dissolution profiles of the four products. The varying dissolution performance was attributed to the formation of distinct beta-cyclodextrin complexes with varing solubilities.
通过中和一种酸性药物形成了一系列四种β-环糊精复合物(称为产物),以研究药物溶解度对复合物形成的影响以及直接压片的溶出性能。通过在0.05、0.10、0.20和0.30 M的三羟甲基氨基甲烷溶液中用恒定的0.09 Mβ-环糊精浓度中和药物,过滤溶液,并通过加热和真空蒸发除去水分,制备了四种固体产物。这四种产物中药物和水的关系各不相同,因此表明复合物的形成取决于三羟甲基氨基甲烷的浓度。红外光谱、粉末X射线衍射、差示扫描量热法(DSC)、相溶解度和扫描电子显微镜(SEM)技术揭示了这四种产物之间存在明显差异,表明四种产物中的三种是复合物,一种产物要么是弱复合物,要么是物理混合物。紫外(UV)分析没有显示复合物形成的证据。相溶解度结果表明,随着β-环糊精浓度的增加,一种产物的药物溶解度略有增加,而三种产物的药物溶解度没有增加。溶解度没有增加表明形成了不溶性复合物。与纯药物相比,所有含有产物或物理混合物的片剂在水中的药物溶出度均有显著提高。用两种最高浓度的三羟甲基氨基甲烷制备的产物显示出优于所有其他制剂的溶出性能。DSC进行的焓测量是含有这四种产物的片剂溶出性能的良好指标。在没有β-环糊精的情况下通过成盐进行的药物溶出表明,与四种产物的溶出曲线相比,药物盐的溶出情况从较好到较差不等。溶出性能的差异归因于形成了具有不同溶解度的不同β-环糊精复合物。